- Previous Close
617.65 - Open
617.60 - Bid 616.50 x --
- Ask 620.00 x --
- Day's Range
611.05 - 621.95 - 52 Week Range
498.00 - 814.00 - Volume
3,117 - Avg. Volume
6,342 - Market Cap (intraday)
12.368B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
12.80 - EPS (TTM)
48.23 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield 1.80 (0.29%)
- Ex-Dividend Date Sep 13, 2024
- 1y Target Est
--
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. The company was incorporated in 1979 and is based in Ahmedabad, India.
www.lincolnpharma.com1,687
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LINCOLN.BO
View MorePerformance Overview: LINCOLN.BO
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LINCOLN.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LINCOLN.BO
View MoreValuation Measures
Market Cap
12.37B
Enterprise Value
10.38B
Trailing P/E
12.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.10
Price/Book (mrq)
1.93
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
7.57
Financial Highlights
Profitability and Income Statement
Profit Margin
16.54%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.92B
Net Income Avi to Common (ttm)
979.63M
Diluted EPS (ttm)
48.23
Balance Sheet and Cash Flow
Total Cash (mrq)
1.53B
Total Debt/Equity (mrq)
0.18%
Levered Free Cash Flow (ttm)
--